Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.60 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.54 |
| ▸ | GNPAT | O15228 | 1/20 | 0.47 |
| ▸ | GSR | P00390 | 1/20 | 0.47 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.46 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3215126 | 1.00 | FOLH1 (0.60) | FOLH1SLC6A5GNPATGSRSLC15A2 | |
| Ethylene SCHEMBL6545172 | 0.96 | FOLH1 (0.57) | FOLH1SLC6A5GNPATGSRSLC15A2 | |
| SCHEMBL3223579 | 0.94 | FOLH1 (0.53) | FOLH1SLC6A5GNPATGSRSLC15A2 | |
| SCHEMBL4814393 | 0.89 | FOLH1 (0.60) | FOLH1SLC6A5GNPATGSRSLC15A2 | |
| SCHEMBL22689761 | 0.88 | FOLH1 (0.59) | FOLH1SLC6A5GNPATGSRSLC15A2 | |
| SCHEMBL1455499 | 0.87 | FOLH1 (0.62) | FOLH1SLC6A5GNPATGSRSLC15A2 | |
| SCHEMBL1455498 | 0.87 | FOLH1 (0.62) | FOLH1SLC6A5GNPATGSRSLC15A2 | |
| SCHEMBL3460653 | 0.87 | FOLH1 (0.62) | FOLH1SLC6A5GNPATGSRSLC15A2 | |
| SCHEMBL22689842 | 0.86 | SLC6A5 (0.59) | FOLH1SLC6A5GNPATGSRSLC15A2 | |
| SCHEMBL29539958 | 0.86 | FOLH1 (0.57) | FOLH1SLC6A5GNPATGSRSLC15A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130855-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260053806-A1 | GAMMA POLYGLUTAMATED METHOTREXATE AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20250319123-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250319188-A1 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250222001-A1 | GAMMA POLYGLUTAMATED METHOTREXATE AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2025-07-10 | — | — | US | disclosed |
| US-12350271-B2 | Gamma polyglutamated aminopterin and uses thereof | L.E.A.F. HOLDINGS GROUP LLC (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250213578-A1 | ALPHA POLYGLUTAMATED AMINOPTERIN AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2025-07-03 | — | — | US | disclosed |
| US-12310966-B2 | Alpha polyglutamated aminopterin and uses thereof | L.E.A.F. HOLDINGS GROUP LLC (US) | 2025-05-27 | — | — | US | disclosed |
| US-20250161455-A1 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2025-05-22 | — | — | US | disclosed |
| US-12290518-B2 | Gamma polyglutamated methotrexate and uses thereof | L.E.A.F. HOLDINGS GROUP LLC (US) | 2025-05-06 | — | — | US | disclosed |
| US-12220431-B2 | Gamma polyglutamated antifolates and uses thereof | L.E.A.F. HOLDINGS GROUP LLC (US) | 2025-02-11 | — | — | US | disclosed |
| US-12128046-B2 | Alpha polyglutamated methotrexate and uses thereof | L.E.A.F. HOLDINGS GROUP LLC (US) | 2024-10-29 | — | — | US | disclosed |
| US-12076402-B2 | Alpha polyglutamated antifolates and uses thereof | L.E.A.F. HOLDINGS GROUP LLC (US) | 2024-09-03 | — | — | US | disclosed |
| WO-2024010957-A2 | NECTIN-4 MINIPROTEIN CONJUGATES | AKTIS ONCOLOGY, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| EP-3692054-A1 | MODIFIED STRAINS FOR THE PRODUCTION OF RECOMBINANT SILK | Bolt Threads, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| WO-2019178267-A2 | INDUCTIVE REGENERATION OF THE AIRWAY BY TRANSCRIPTIONAL FACTOR MODULATION OF GLANDULAR MYOEPITHELIAL STEM CELLS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2019-09-19 | — | — | WO | disclosed |
| WO-2019070246-A1 | MODIFIED STRAINS FOR THE PRODUCTION OF RECOMBINANT SILK | BOLT THREADS, INC . (US) | 2019-04-11 | — | — | WO | disclosed |
| EP-1590440-A4 | CELL-KILLING MOLECULES AND METHODS OF USE THEREOF | PALO ALTO INST OF MOLECULAR ME (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-1590440-A2 | CELL-KILLING MOLECULES AND METHODS OF USE THEREOF | Palo Alto Institute of Molecular Medicine (US) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004070012-A2 | CELL-KILLING MOLECULES AND METHODS OF USE THEREOF | PALO ALTO INSTITUTE OF MOLECULAR MEDICINE (US) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12220431-B2 | Gamma polyglutamated antifolates and uses thereof | GGCT, IFNG, FPGS | FOLH1 13/4885SLC6A5 1567/4885GNPAT 2111/4885 |
| US-20250319123-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | GGCT, IFNG, FPGS | FOLH1 13/4885SLC6A5 1567/4885GNPAT 2111/4885 |
| US-20250213578-A1 | ALPHA POLYGLUTAMATED AMINOPTERIN AND USES THEREOF | FOLH1, QPCT, SGTA | FOLH1 1/4885SLC6A5 954/4885GNPAT 2290/4885 |
| US-20250161455-A1 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | FPGS, GGCT, FOLR1 | FOLH1 7/4885SLC6A5 1708/4885GNPAT 1977/4885 |
| US-12076402-B2 | Alpha polyglutamated antifolates and uses thereof | FPGS, GGCT, FOLR1 | FOLH1 7/4885SLC6A5 1708/4885GNPAT 1977/4885 |
| US-20250319188-A1 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | FPGS, GGCT, FOLR1 | FOLH1 7/4885SLC6A5 1708/4885GNPAT 1977/4885 |
| US-20250222001-A1 | GAMMA POLYGLUTAMATED METHOTREXATE AND USES THEREOF | IFNG, FPGS, MTX1 | FOLH1 20/4885SLC6A5 2445/4885GNPAT 3103/4885 |
| US-20260053806-A1 | GAMMA POLYGLUTAMATED METHOTREXATE AND USES THEREOF | FPGS, PDF, STOML2 | FOLH1 23/4885SLC6A5 1042/4885GNPAT 4651/4885 |
| US-20260130855-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | FOLR2, FPGS, FOLR1 | FOLH1 8/4885SLC6A5 1203/4885GNPAT 4727/4885 |
| US-12128046-B2 | Alpha polyglutamated methotrexate and uses thereof | MTX1, MTX2, IFNG | FOLH1 12/4885SLC6A5 2267/4885GNPAT 3126/4885 |
| US-12310966-B2 | Alpha polyglutamated aminopterin and uses thereof | FOLH1, QPCT, SGTA | FOLH1 1/4885SLC6A5 954/4885GNPAT 2290/4885 |
| US-12290518-B2 | Gamma polyglutamated methotrexate and uses thereof | IFNG, FPGS, MTX1 | FOLH1 20/4885SLC6A5 2445/4885GNPAT 3103/4885 |
| US-12350271-B2 | Gamma polyglutamated aminopterin and uses thereof | QPCT, SGTA, IFNG | FOLH1 8/4885SLC6A5 1376/4885GNPAT 2536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.